Still hope on Kintor due to the new announcement Treatment 12/20/2023
The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
View this post in the Community →
Similar Community Posts Join
5 / 358 resultscommunity Received Kintor’s KX-826 Today
A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.
community What the Breezula Phase III results mean & realistic timeline
Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.
community KX-826: Long-Term Safety Results are out!
KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Related Research
6 / 164 results
research Androgenetic Alopecia: Therapy Update
There are many treatments for common hair loss, but more trials are needed to decide which are best.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research Development and Validation of Androgen-Induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
The mouse models are effective for testing new hair loss treatments.
research Mechanism Exploration of the Combined Use of Minoxidil with Natural Compounds Ginsenoside Rg3 and Glycyrrhizic Acid for Enhancing Androgenic Alopecia Therapy
The study explores the combined use of minoxidil (MXD) with natural compounds ginsenoside Rg3 and glycyrrhizic acid (GA) to enhance therapy for androgenic alopecia (AGA). The research highlights that activating the Wnt/β-catenin pathway is crucial for treating AGA. While minoxidil is more effective in up-regulating this pathway, Rg3 and GA are effective in inhibiting 5-α reductase and antagonizing androgen receptors, addressing the root causes of AGA. However, Rg3 and GA alone have limited effects on repairing damaged hair follicles. The combination of these compounds with MXD targets both symptoms and causes of AGA, offering a more comprehensive treatment approach. The study involved molecular docking and tests on C57BL/6 mice, providing a theoretical basis for clinical application.